Study Participants Wanted

Note: Only studies being conducted by the UMass Department of Psychiatry will be listed here. No other entries accepted.

Members of the department wishing to submit information like this should use the format below, include a subject line of “Study Participants Wanted,” and email it to psychiatrycommunications@umassmed.edu.


RAP-MD-03 Study

We are currently enrolling participants in a clinical research study to evaluate the effectiveness and safety of an investigational drug.  The study will examine if the study drug can treat symptoms of a major depressive episode while a person is on a stable dose of another antidepressant therapy. Participants must:

  • be 18 to 65 years of age
  • have been diagnosed with depression
  • be experiencing current symptoms of depression despite taking an antidepressant medication
  • must be comfortable receiving IV medication
  • not be pregnant or have plans to become pregnant

Subjects will receive study drug and study-related care at no cost.  Study participation will last up to 5 weeks, and then subjects will potentially be able to enroll in long-term follow-up studies afterward. Compensation for time and travel will be provided for qualified participants.

Contact Chelsea Kosma
WIRB20161803 


The Substance Use Study

Have you or someone you know been diagnosed with Schizophrenia or Schizoaffective Disorder?
Do you or that person also use alcohol, marijuana, or any other drugs?
If so, you or someone you know may be eligible to participate in a research study conducted at UMass Medical School.
The purpose of this study is to see whether brexpiprazole, an investigational drug, can help reduce substance use in individuals diagnosed with schizophrenia or schizoaffective disorders
Your participation in the study will last 12 weeks, and you will be compensated for your time.
If you are interested and would like more information, please call 508-856-MIND (6463) or email MIND@umassmed.edu.

Funding Source: Otsuka Pharmaceuticals
IRB Docket # H00014611


The Treatment-Resistant Study

Are you above the age of 18, and diagnosed with schizophrenia?
If so, you may be eligible to participate in a research study conducted at UMass Medical School
The purpose of this study is to see whether Lu AF35700, an experimental drug, is safe and effective for the possible treatment of treatment-resistant schizophrenia.
You will be compensated for your time. If you are interested and would like more information,
please call 508-856-MIND (6463) or email MIND@umassmed.edu

Funding Source: H. Lundbeck A/S
IRB Docket # H00014572


ESKETINTRD3001 Study

We are currently enrolling participants in a clinical research study to look at the effectiveness and safety of an investigational medication (given as a nasal spray) in patients with depression who have not responded to prior treatment with an antidepressant and currently taking a different antidepressant.

Participants must:

  • be 18 to 64 years of age
  • have been diagnosed with depression
  • be experiencing current symptoms of depression despite taking antidepressant medications
  • have not responded to prior treatment with an antidepressant and currently taking a different antidepressant
  • must be comfortable with using a nasal spray
  • not be pregnant or have plans to become pregnant

Subjects will receive study drug and study-related care at no cost. Study participation will last up to 35 weeks. Compensation for time and travel will be provided for qualified participants.

Contact Chelsea Kosma @ 508-856-5312
Docket # H-00011026


The Depression Relapse Trial

Individuals that are currently suffering from depression are invited to participate in a research study to determine the effectiveness and safety of vortioxetine in preventing relapse in depression for those subjects who respond to treatment with vortioxetine. Study participation will last up to 55 weeks and subjects will receive the study drug vortioxetine.

Participants must be:

  • 18 to 75 years of age
  • suffering from recurrent Major Depressive Disorder
  • experiencing current symptoms of depression
  • not be pregnant or have plans to become pregnant

Subjects will receive study drug and study-related care at no cost. Compensation provided.

Contact Michelangela Yusif @ 774-455-4136
Docket # H-00007086


Outpatient Couple Therapy for Service Members and Veterans with Alcohol-Related Concerns

The Alcohol Behavioral Couple Therapy Military treatment research program is specifically designed to help service members or veterans and their partners to learn skills that will help to reduce drinking and to improve relationship functioning.

The program will include a thorough assessment, 15 weekly outpatient sessions with a spouse, partner or family member (free of charge), and a follow-up session.  Compensation will be provided for the intake and follow-up sessions.

Below are the major inclusion criteria:

  • Be a service member or veteran of the U.S. Military (all branches welcome including National Guard and Reserves)
  • Have a drinking habit you want to change
  • Be 18 or older
  • Have a significant other who can attend sessions with you (spouse, dating partner, family member)

For more information, please contact Emily Starratt (508-856-8745) or Dr. Beth Epstein (732-995-7315).

IRB# H-3823


A Psychotic Disorders Program Research Study

Exenatide weekly injection as an adjunctive treatment in patients with schizophrenia

Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking?

If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months).

You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Funding Source: Stanley Medical Research Institute
IRB Docket# H00004119